The global drug discovery informatics market is projected to grow from $4.06 billion in 2025 to $4.63 billion in 2026, a 14.1% compound annual growth rate, before reaching $7.74 billion by 2030 at a 13.7% CAGR. ResearchAndMarkets.com added its Drug Discovery Informatics Market Report 2026 to its offering on Sept. 14, 2026. Growth is being driven by more complex pharmaceutical research, expanding clinical-trial data, computational chemistry, bioinformatics, artificial intelligence, precision medicine, collaborative research platforms and predictive modeling. Drug discovery informatics uses software and data-analysis systems to support tasks including virtual screening, molecular modeling, target identification and validation, and management of scientific and clinical information. The report identifies AI-driven platforms, cloud-based solutions, big-data analytics and integration with laboratory systems as major trends. Rising chronic disease prevalence is also supporting demand; Diabetes UK estimated that approximately 4.4 million people in the UK had a diabetes diagnosis in 2022-23, with around 8% having type 1 diabetes and approximately 90% having type 2 diabetes. Google Cloud launched its Target and Lead Identification Suite and Multiomics Suite in May 2023, while Recursion Pharmaceuticals acquired Cyclica for $40 million that month. North America was the largest regional market in 2025, while Asia-Pacific is expected to grow fastest during the forecast period.